Spotlight On... Sosei scouts for pipeline partners; Ocular Therapeutix maps out Phase III; and much more...

Japanese drug developer Sosei is on the hunt for global partners for its pipeline treatments, hoping to make good on the assets picked up in its $400 million acquisition of Heptares Therapeutics last year. CEO Shinichi Tamura told Bloomberg that the company is hoping to replicate its success in past deals with Pfizer ($PFE), AstraZeneca ($AZN) and Novartis ($NVS), adding that a few new partnerships "could be the first big news in 2016." The company padded its pipeline with the Heptares deal and is now at work on early-stage treatments for Alzheimer's disease, migraines, diabetes and ADHD. More

@FierceBiotech: Survey: Biopharma gets a bad grade on gender diversity. Report | Follow @FierceBiotech

@JohnCFierce: It's been fun watching the traffic/responses on the gender issue last few wks. There's a whole segment of the male audience tuning it out. | Follow @JohnCFierce

@DamianFierce: happy birthday to Wizards legend Michael Jodran. | Follow @DamianFierce

> Drug developer Athenex secured a $220 million commitment from the state of New York to help it build a manufacturing plant in Buffalo, planning to eventually employ about 900 people. News

> Ocular Therapeutix ($OCUL) laid out plans for taking its glaucoma drug through Phase III and toward the market, planning to start the first of two late-stage trials in the third quarter of this year. Release

Pharma News

@FiercePharma: ICYMI yesterday: With pricing power waning, time for Big Pharma to become a lean, mean, well-oiled machine. Article | Follow @FiercePharma

@EricPFierce: Merck adding a couple hundreds manufacturing jobs in Ireland. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Express Scripts steps up its Valeant feud with microscopic look at every claim. Story | Follow @CarlyHFierce

> Pfizer whistleblowers set to collect $59M in Medicaid fraud suit. Article

> Pricey specialty meds get the DTC treatment even when target markets are small. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: GSK partners with Belgian neurostim startup in bioelectronic medicine research. Article | Follow @FierceMedDev

@EmilyWFierce: Kentucky lawmaker proposed a bill that would require men to get a note from their spouse for a Viagra Rx. NYT story | Follow @EmilyWFierce

> Virtual reality startup reels in $100M for rehabilitation device. Report

> Singaporean smart chip could enable next-gen wireless neural implants. Article

Biotech Research News

> Scientists use old vaccination method to beat new viruses. Article

> Johns Hopkins scientists create 'mini-brains' for neurodegeneration researchers. Story

> Penn team shines a light on creating brown fat to fight diabetes. Report

> Hype around worm study on potential Alzheimer's treatment is derided. Item

> Analysis: Scrap the NIH funding model and switch to a lottery. More

Vaccines News

> U.K. report: Vaccines could help in superbug fight. Item

> Walter Reed kicks off PhI trial of Inovio's MERS vaccine. News

> Sanofi ships 1M Dengvaxia doses to Philippines, in talks for 3M more at €20 a dose. Report

> Russia to test Ebola candidate in Guinea: AFP. Story

> NIH, Bharat Biotech hold the lead in Zika vaccine race: WHO. Article

Pharma Marketing News

> It's not just payers waiting on PCSK9 outcomes data. Doctors are holding back, too. Story

> Instagram updates could help pharma tap new audiences--and maybe get creative, too. Report

> Can BIO's heartfelt image campaign win hearts and minds? Pharma skeptics aren't convinced. More

> McCann Health adds new chief growth officer to get ahead in changing industry. Story

> Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.